MediWound Ltd. (MDWD) 10-Year Financial Performance & Capital Metrics

MDWD • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesDiagnostics & Immune Monitoring

AboutMediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.Show more

Revenue $20M +8.2%
EBITDA -$18M -26.1%
Net Income -$30M -350.0%
EPS (Diluted) -3.03 -304.0%
Gross Margin 8.81% -44.2%
EBITDA Margin -88.52% -16.5%
Operating Margin -95.85% -15.5%
Net Margin -149.46% -315.8%
ROE -96.33% -204.9%
ROIC -52.85% +91.0%
Debt/Equity 0.22 +10.7%
Interest Coverage -34.55 +25.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 8.6% over 5 years
✗Shares diluted 10.5% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y54.62%

5Y-8.65%

3Y-5.24%

TTM6.15%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM26.57%

EPS CAGR

10Y-

5Y-

3Y-

TTM34.58%

ROCE

10Y Avg-34.84%

5Y Avg-41.48%

3Y Avg-34.51%

Latest-37.79%

Peer Comparison

Diagnostics & Immune Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TECHBio-Techne Corporation	10.9B	69.96	152.09	5.23%	6.41%	3.97%	2.35%	0.23
SPRYARS Pharmaceuticals, Inc.	1.1B	11.09	142.00	2970.63%	-56.06%	-54.21%	1.18%	0.00
VCYTVeracyte, Inc.	3.24B	41.00	132.26	23.46%	6.12%	2.41%	1.97%	0.04
CSBRChampions Oncology, Inc.	99.56M	7.17	21.73	13.54%	4.32%	59.65%	7.03%	1.62
MDXGMiMedx Group, Inc.	851.59M	5.75	20.54	8.52%	10.38%	17.09%	7.58%	0.13
LTRNLantern Pharma Inc.	39.26M	3.51	-0.00			-197.36%		0.01
SEERSeer, Inc.	107.44M	1.91	-1.37	-8.13%	-486.02%	-29.19%		0.08
IMDXInsight Molecular Diagnostics Inc.	189.76M	6.62	-1.42	25.15%	-13.81%	-14.81%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	601K	1.56M	2.5M	3.4M	31.79M	21.76M	23.76M	26.5M	18.69M	20.22M
Revenue Growth %	1.32%	1.59%	0.6%	0.36%	8.35%	-0.32%	0.09%	0.12%	-0.29%	0.08%
Cost of Goods Sold+	2.6M	2.27M	1.69M	2.19M	12.49M	14.75M	15.63M	14.18M	15.74M	18.44M
COGS % of Revenue	4.33%	1.46%	0.68%	0.64%	0.39%	0.68%	0.66%	0.54%	0.84%	0.91%
Gross Profit+	-2M	-712K	808K	1.21M	19.3M	7.01M	8.14M	12.32M	2.95M	1.78M
Gross Margin %	-3.33%	-0.46%	0.32%	0.36%	0.61%	0.32%	0.34%	0.46%	0.16%	0.09%
Gross Profit Growth %	0.22%	0.64%	2.13%	0.5%	14.95%	-0.64%	0.16%	0.51%	-0.76%	-0.4%
Operating Expenses+	19.22M	19.44M	14.49M	11.96M	13.64M	15.85M	19.36M	19.98M	18.45M	21.16M
OpEx % of Revenue	31.99%	12.48%	5.81%	3.52%	0.43%	0.73%	0.81%	0.75%	0.99%	1.05%
Selling, General & Admin	13.21M	12.4M	9.07M	7.93M	9.01M	8.5M	9.45M	10.37M	11.38M	12.91M
SG&A % of Revenue	21.98%	7.96%	3.64%	2.33%	0.28%	0.39%	0.4%	0.39%	0.61%	0.64%
Research & Development	6.02M	7.04M	5.42M	4.02M	4.63M	7.35M	9.9M	9.61M	7.07M	8.25M
R&D % of Revenue	10.01%	4.52%	2.17%	1.18%	0.15%	0.34%	0.42%	0.36%	0.38%	0.41%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-21.23M	-20.16M	-13.69M	-10.75M	5.67M	-8.84M	-11.22M	-7.66M	-15.5M	-19.38M
Operating Margin %	-35.32%	-12.94%	-5.48%	-3.16%	0.18%	-0.41%	-0.47%	-0.29%	-0.83%	-0.96%
Operating Income Growth %	0.01%	0.05%	0.32%	0.21%	1.53%	-2.56%	-0.27%	0.32%	-1.02%	-0.25%
EBITDA+	-20.72M	-19.57M	-13.12M	-10.17M	6.82M	-7.75M	-9.98M	-6.39M	-14.2M	-17.9M
EBITDA Margin %	-34.48%	-12.56%	-5.26%	-2.99%	0.21%	-0.36%	-0.42%	-0.24%	-0.76%	-0.89%
EBITDA Growth %	0.01%	0.06%	0.33%	0.22%	1.67%	-2.14%	-0.29%	0.36%	-1.22%	-0.26%
D&A (Non-Cash Add-back)	503K	589K	567K	577K	1.15M	1.09M	1.24M	1.27M	1.3M	1.48M
EBIT	-21.67M	-18.89M	-14.53M	-5.67M	2.27M	-9.08M	-13.36M	-19.36M	-6.2M	-29.6M
Net Interest Income+	288K	414K	349K	412K	227K	97K	-156K	108K	2.01M	1.49M
Interest Income	288K	414K	349K	412K	434K	297K	11K	270K	2.34M	2.05M
Interest Expense	0	0	0	0	207K	200K	167K	162K	335K	561K
Other Income/Expense	-444K	1.27M	-846K	5.08M	-3.6M	-436K	-2.3M	-11.86M	8.97M	-10.78M
Pretax Income+	-21.67M	-18.89M	-14.53M	-5.67M	2.07M	-9.28M	-13.52M	-19.52M	-6.53M	-30.16M
Pretax Margin %	-36.06%	-12.12%	-5.82%	-1.67%	0.06%	-0.43%	-0.57%	-0.74%	-0.35%	-1.49%
Income Tax+	0	0	8.46M	0	0	0	27K	78K	185K	61K
Effective Tax Rate %	1.02%	1%	1.52%	0.19%	2.4%	0.99%	1%	1%	1.03%	1%
Net Income+	-22.09M	-18.89M	-22.15M	-1.06M	4.96M	-9.2M	-13.55M	-19.6M	-6.72M	-30.22M
Net Margin %	-36.75%	-12.12%	-8.87%	-0.31%	0.16%	-0.42%	-0.57%	-0.74%	-0.36%	-1.49%
Net Income Growth %	-0.17%	0.15%	-0.17%	0.95%	5.69%	-2.86%	-0.47%	-0.45%	0.66%	-3.5%
Net Income (Continuing)	-21.67M	-18.89M	-14.53M	-5.67M	2.07M	-9.28M	-13.55M	-19.6M	-6.72M	-30.22M
Discontinued Operations	-417K	0	-7.62M	4.61M	2.89M	80K	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-7.13	-6.05	-6.64	-0.28	1.26	-2.38	-3.48	-3.93	-0.75	-3.03
EPS Growth %	-0.07%	0.15%	-0.1%	0.96%	5.5%	-2.89%	-0.46%	-0.13%	0.81%	-3.04%
EPS (Basic)	-7.13	-6.05	-6.64	-0.28	1.26	-2.38	-3.48	-3.93	-0.75	-3.03
Diluted Shares Outstanding	3.1M	3.12M	3.33M	3.87M	3.88M	3.89M	3.89M	4.99M	9.01M	9.96M
Basic Shares Outstanding	3.1M	3.12M	3.33M	3.87M	3.88M	3.89M	3.89M	4.99M	9.01M	9.96M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	50.4M	33.61M	41.52M	32.71M	35.62M	26.19M	14.95M	45.84M	49.7M	52.16M
Cash & Short-Term Investments	45.77M	30.03M	36.07M	23.63M	29.46M	21.58M	11.05M	33.9M	41.54M	43.16M
Cash Only	42.5M	28.87M	36.07M	6.72M	7.24M	17.38M	11.05M	33.9M	11.87M	9.15M
Short-Term Investments	3.27M	1.16M	0	16.92M	22.04M	4.02M	0	0	29.68M	34.01M
Accounts Receivable	2.91M	2.74M	3.44M	7.27M	4.33M	2.84M	2.27M	9.7M	4.42M	5.85M
Days Sales Outstanding	1.77K	641.68	502.46	780.01	49.77	47.63	34.82	133.56	86.32	105.63
Inventory	1.72M	844K	1.89M	1.68M	1.61M	1.38M	1.2M	1.96M	2.85M	2.69M
Days Inventory Outstanding	240.3	135.71	407.81	279.87	47.15	34.14	28.03	50.54	66	53.28
Other Current Assets	-205K	-224K	0	0	408K	257K	0	363K	167K	0
Total Non-Current Assets+	2.13M	2.15M	2.62M	2.56M	4.97M	4.88M	4.79M	4.18M	16.76M	21.33M
Property, Plant & Equipment	1.04M	1.28M	1.92M	2.02M	4.53M	4.51M	4.03M	3.58M	15.93M	20.8M
Fixed Asset Turnover	0.58x	1.22x	1.30x	1.68x	7.01x	4.82x	5.90x	7.40x	1.17x	0.97x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	896K	773K	635K	495K	429K	363K	297K	231K	165K	99K
Long-Term Investments	0	0	0	0	0	0	469K	364K	490K	439K
Other Non-Current Assets	192K	103K	56K	48K	6K	-4.88M	-4.32M	-3.81M	183K	0
Total Assets+	52.52M	35.76M	44.13M	35.28M	40.59M	31.07M	19.74M	50.02M	66.46M	73.5M
Asset Turnover	0.01x	0.04x	0.06x	0.10x	0.78x	0.70x	1.20x	0.53x	0.28x	0.28x
Asset Growth %	-0.26%	-0.32%	0.23%	-0.2%	0.15%	-0.23%	-0.36%	1.53%	0.33%	0.11%
Total Current Liabilities+	5.21M	5.38M	5.43M	4.9M	10.37M	8.27M	10.72M	12.06M	10.83M	26.54M
Accounts Payable	1.12M	1.46M	3.25M	2.71M	4.07M	2.99M	4.69M	5.66M	4.22M	4.1M
Days Payables Outstanding	157.35	234.11	702.97	452.29	118.88	74.02	109.61	145.63	97.93	81.07
Short-Term Debt	0	0	0	0	0	0	0	0	0	418K
Deferred Revenue (Current)	91K	122K	131K	198K	249K	462K	543K	63K	24K	12K
Other Current Liabilities	276K	2.24M	0	452K	3.74M	2.9M	3.85M	3.87M	1.86M	17.73M
Current Ratio	9.68x	6.25x	7.64x	6.68x	3.43x	3.17x	1.39x	3.80x	4.59x	1.97x
Quick Ratio	9.35x	6.09x	7.30x	6.34x	3.28x	3.00x	1.28x	3.64x	4.33x	1.86x
Cash Conversion Cycle	1.85K	543.27	207.3	607.59	-21.96	7.75	-46.76	38.47	54.38	77.84
Total Non-Current Liabilities+	23.85M	22.61M	29.08M	21.41M	15.05M	15.53M	13.61M	27.05M	16.74M	15.8M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	2.01M	1.74M	1.39M	846K	6.35M	6.51M
Deferred Tax Liabilities	0	0	0	0	243K	292K	288K	0	0	0
Other Non-Current Liabilities	23.85M	21.59M	28.09M	20.25M	11.91M	12.56M	12.1M	26.2M	10.39M	8.55M
Total Liabilities	29.05M	27.99M	34.52M	26.3M	25.42M	23.8M	24.33M	39.1M	34.86M	42.34M
Total Debt+	0	0	0	0	2.01M	1.74M	1.39M	846K	6.35M	6.93M
Net Debt	-42.5M	-28.87M	-36.07M	-6.72M	-5.24M	-15.63M	-9.65M	-33.05M	-5.52M	-2.22M
Debt / Equity	-	-	-	-	0.13x	0.24x	-	0.08x	0.20x	0.22x
Debt / EBITDA	-	-	-	-	0.29x	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-0.77x	-	-	-	-	-
Interest Coverage	-	-	-	-	27.37x	-44.20x	-67.19x	-47.29x	-46.27x	-34.55x
Total Equity+	23.47M	7.77M	9.62M	8.97M	15.17M	7.27M	-4.58M	10.91M	31.59M	31.15M
Equity Growth %	-0.45%	-0.67%	0.24%	-0.07%	0.69%	-0.52%	-1.63%	3.38%	1.89%	-0.01%
Book Value per Share	7.58	2.49	2.89	2.32	3.91	1.87	-1.18	2.19	3.51	3.13
Total Shareholders' Equity	23.47M	7.77M	9.62M	8.97M	15.17M	7.27M	-4.58M	10.91M	31.59M	31.15M
Common Stock	60K	60K	75K	75K	75K	75K	75K	143K	184K	215K
Retained Earnings	-88.38M	-107.26M	-129.41M	-130.72M	-125.76M	-134.96M	-148.51M	-168.11M	-174.82M	-205.05M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-16K	-9K	-38K	-25K	-17K	-40K	-19K	-5K	-18K	-11K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-19.6M	-16.45M	-16.45M	-12.15M	8.29M	-6.89M	-8.92M	-11.88M	-10.46M	-13.62M
Operating CF Margin %	-32.61%	-10.56%	-6.59%	-3.57%	0.26%	-0.32%	-0.38%	-0.45%	-0.56%	-0.67%
Operating CF Growth %	-0.19%	0.16%	-0%	0.26%	1.68%	-1.83%	-0.29%	-0.33%	0.12%	-0.3%
Net Income	-22.09M	-18.89M	-22.15M	-1.06M	4.96M	-9.2M	-13.55M	-19.6M	-6.72M	-30.22M
Depreciation & Amortization	503K	589K	567K	577K	1.15M	1.09M	1.24M	1.27M	1.3M	1.48M
Stock-Based Compensation	2.66M	3.17M	1.36M	645K	1.23M	1.32M	1.67M	1.95M	1.94M	3.14M
Deferred Taxes	90K	125K	-1.64M	201K	-1.86M	-373K	-124K	0	0	0
Other Non-Cash Items	-1.04M	-3.43M	7.85M	-11.51M	-1.69M	323K	1.69M	11.74M	-9.33M	10.71M
Working Capital Changes	275K	1.98M	-2.45M	-1.01M	4.49M	-61K	162K	-7.24M	2.34M	1.27M
Change in Receivables	-181K	-107K	28K	-211K	-3.55M	1.39M	929K	-7.58M	4.76M	-1.02M
Change in Inventory	-273K	873K	-1.04M	206K	67K	141K	257K	-721K	-906K	187K
Change in Payables	-76K	331K	-135K	-536K	1.35M	-1.1M	1.72M	414K	-594K	406K
Cash from Investing+	36.05M	1.82M	437K	-17.04M	-6.9M	17.39M	3.55M	-481K	-34.32M	-8.4M
Capital Expenditures	-406K	-701K	-1.07M	-534K	-792K	-923K	-489K	-555K	-6.46M	-6.27M
CapEx % of Revenue	0.68%	0.45%	0.43%	0.16%	0.02%	0.04%	0.02%	0.02%	0.35%	0.31%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	36.45M	2.52M	349K	-16.51M	-1.05M	274K	35K	74K	-27.86M	-2.12M
Cash from Financing+	778K	907K	23M	46K	-1.01M	-629K	-1.05M	35.76M	22.92M	19.39M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	778K	907K	337K	46K	-376K	-121K	-1.05M	-2.62M	-1.99M	-1.84M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-20.01M	-17.15M	-17.53M	-12.69M	7.5M	-7.82M	-9.4M	-12.44M	-16.93M	-19.9M
FCF Margin %	-33.29%	-11.01%	-7.02%	-3.73%	0.24%	-0.36%	-0.4%	-0.47%	-0.91%	-0.98%
FCF Growth %	-0.18%	0.14%	-0.02%	0.28%	1.59%	-2.04%	-0.2%	-0.32%	-0.36%	-0.18%
FCF per Share	-6.46	-5.49	-5.26	-3.28	1.93	-2.01	-2.42	-2.49	-1.88	-2.00
FCF Conversion (FCF/Net Income)	0.89x	0.87x	0.74x	11.50x	1.67x	0.75x	0.66x	0.61x	1.56x	0.45x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-66.59%	-120.9%	-254.73%	-11.37%	41.05%	-81.96%	-1007.51%	-619.05%	-31.6%	-96.33%
Return on Invested Capital (ROIC)	-	-	-	-	69.71%	-844.59%	-	-	-589.54%	-52.85%
Gross Margin	-333.44%	-45.7%	32.37%	35.58%	60.72%	32.21%	34.24%	46.5%	15.77%	8.81%
Net Margin	-3675.21%	-1212.13%	-887.38%	-31.08%	15.59%	-42.26%	-57.03%	-73.97%	-35.94%	-149.46%
Debt / Equity	-	-	-	-	0.13x	0.24x	-	0.08x	0.20x	0.22x
Interest Coverage	-	-	-	-	27.37x	-44.20x	-67.19x	-47.29x	-46.27x	-34.55x
FCF Conversion	0.89x	0.87x	0.74x	11.50x	1.67x	0.75x	0.66x	0.61x	1.56x	0.45x
Revenue Growth	132.05%	159.23%	60.21%	36.26%	834.7%	-31.54%	9.19%	11.5%	-29.48%	8.22%

Revenue by Geography

	2020
USA	18.03M
USA Growth	-

Frequently Asked Questions

Growth & Financials

MediWound Ltd. (MDWD) reported $20.9M in revenue for fiscal year 2024.

MediWound Ltd. (MDWD) grew revenue by 8.2% over the past year. This is steady growth.

MediWound Ltd. (MDWD) reported a net loss of $20.6M for fiscal year 2024.

Dividend & Returns

MediWound Ltd. (MDWD) has a return on equity (ROE) of -96.3%. Negative ROE indicates the company is unprofitable.

MediWound Ltd. (MDWD) had negative free cash flow of $18.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

MediWound Ltd. (MDWD) 10-Year Financial Performance & Capital Metrics

MDWD • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesDiagnostics & Immune Monitoring

Revenue $20M +8.2%
EBITDA -$18M -26.1%
Net Income -$30M -350.0%
EPS (Diluted) -3.03 -304.0%
Gross Margin 8.81% -44.2%
EBITDA Margin -88.52% -16.5%
Operating Margin -95.85% -15.5%
Net Margin -149.46% -315.8%
ROE -96.33% -204.9%
ROIC -52.85% +91.0%
Debt/Equity 0.22 +10.7%
Interest Coverage -34.55 +25.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 8.6% over 5 years
✗Shares diluted 10.5% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y54.62%

5Y-8.65%

3Y-5.24%

TTM6.15%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM26.57%

EPS CAGR

10Y-

5Y-

3Y-

TTM34.58%

ROCE

10Y Avg-34.84%

5Y Avg-41.48%

3Y Avg-34.51%

Latest-37.79%

Peer Comparison

Diagnostics & Immune Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TECHBio-Techne Corporation	10.9B	69.96	152.09	5.23%	6.41%	3.97%	2.35%	0.23
SPRYARS Pharmaceuticals, Inc.	1.1B	11.09	142.00	2970.63%	-56.06%	-54.21%	1.18%	0.00
VCYTVeracyte, Inc.	3.24B	41.00	132.26	23.46%	6.12%	2.41%	1.97%	0.04
CSBRChampions Oncology, Inc.	99.56M	7.17	21.73	13.54%	4.32%	59.65%	7.03%	1.62
MDXGMiMedx Group, Inc.	851.59M	5.75	20.54	8.52%	10.38%	17.09%	7.58%	0.13
LTRNLantern Pharma Inc.	39.26M	3.51	-0.00			-197.36%		0.01
SEERSeer, Inc.	107.44M	1.91	-1.37	-8.13%	-486.02%	-29.19%		0.08
IMDXInsight Molecular Diagnostics Inc.	189.76M	6.62	-1.42	25.15%	-13.81%	-14.81%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	601K	1.56M	2.5M	3.4M	31.79M	21.76M	23.76M	26.5M	18.69M	20.22M
Revenue Growth %	1.32%	1.59%	0.6%	0.36%	8.35%	-0.32%	0.09%	0.12%	-0.29%	0.08%
Cost of Goods Sold+	2.6M	2.27M	1.69M	2.19M	12.49M	14.75M	15.63M	14.18M	15.74M	18.44M
COGS % of Revenue	4.33%	1.46%	0.68%	0.64%	0.39%	0.68%	0.66%	0.54%	0.84%	0.91%
Gross Profit+	-2M	-712K	808K	1.21M	19.3M	7.01M	8.14M	12.32M	2.95M	1.78M
Gross Margin %	-3.33%	-0.46%	0.32%	0.36%	0.61%	0.32%	0.34%	0.46%	0.16%	0.09%
Gross Profit Growth %	0.22%	0.64%	2.13%	0.5%	14.95%	-0.64%	0.16%	0.51%	-0.76%	-0.4%
Operating Expenses+	19.22M	19.44M	14.49M	11.96M	13.64M	15.85M	19.36M	19.98M	18.45M	21.16M
OpEx % of Revenue	31.99%	12.48%	5.81%	3.52%	0.43%	0.73%	0.81%	0.75%	0.99%	1.05%
Selling, General & Admin	13.21M	12.4M	9.07M	7.93M	9.01M	8.5M	9.45M	10.37M	11.38M	12.91M
SG&A % of Revenue	21.98%	7.96%	3.64%	2.33%	0.28%	0.39%	0.4%	0.39%	0.61%	0.64%
Research & Development	6.02M	7.04M	5.42M	4.02M	4.63M	7.35M	9.9M	9.61M	7.07M	8.25M
R&D % of Revenue	10.01%	4.52%	2.17%	1.18%	0.15%	0.34%	0.42%	0.36%	0.38%	0.41%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-21.23M	-20.16M	-13.69M	-10.75M	5.67M	-8.84M	-11.22M	-7.66M	-15.5M	-19.38M
Operating Margin %	-35.32%	-12.94%	-5.48%	-3.16%	0.18%	-0.41%	-0.47%	-0.29%	-0.83%	-0.96%
Operating Income Growth %	0.01%	0.05%	0.32%	0.21%	1.53%	-2.56%	-0.27%	0.32%	-1.02%	-0.25%
EBITDA+	-20.72M	-19.57M	-13.12M	-10.17M	6.82M	-7.75M	-9.98M	-6.39M	-14.2M	-17.9M
EBITDA Margin %	-34.48%	-12.56%	-5.26%	-2.99%	0.21%	-0.36%	-0.42%	-0.24%	-0.76%	-0.89%
EBITDA Growth %	0.01%	0.06%	0.33%	0.22%	1.67%	-2.14%	-0.29%	0.36%	-1.22%	-0.26%
D&A (Non-Cash Add-back)	503K	589K	567K	577K	1.15M	1.09M	1.24M	1.27M	1.3M	1.48M
EBIT	-21.67M	-18.89M	-14.53M	-5.67M	2.27M	-9.08M	-13.36M	-19.36M	-6.2M	-29.6M
Net Interest Income+	288K	414K	349K	412K	227K	97K	-156K	108K	2.01M	1.49M
Interest Income	288K	414K	349K	412K	434K	297K	11K	270K	2.34M	2.05M
Interest Expense	0	0	0	0	207K	200K	167K	162K	335K	561K
Other Income/Expense	-444K	1.27M	-846K	5.08M	-3.6M	-436K	-2.3M	-11.86M	8.97M	-10.78M
Pretax Income+	-21.67M	-18.89M	-14.53M	-5.67M	2.07M	-9.28M	-13.52M	-19.52M	-6.53M	-30.16M
Pretax Margin %	-36.06%	-12.12%	-5.82%	-1.67%	0.06%	-0.43%	-0.57%	-0.74%	-0.35%	-1.49%
Income Tax+	0	0	8.46M	0	0	0	27K	78K	185K	61K
Effective Tax Rate %	1.02%	1%	1.52%	0.19%	2.4%	0.99%	1%	1%	1.03%	1%
Net Income+	-22.09M	-18.89M	-22.15M	-1.06M	4.96M	-9.2M	-13.55M	-19.6M	-6.72M	-30.22M
Net Margin %	-36.75%	-12.12%	-8.87%	-0.31%	0.16%	-0.42%	-0.57%	-0.74%	-0.36%	-1.49%
Net Income Growth %	-0.17%	0.15%	-0.17%	0.95%	5.69%	-2.86%	-0.47%	-0.45%	0.66%	-3.5%
Net Income (Continuing)	-21.67M	-18.89M	-14.53M	-5.67M	2.07M	-9.28M	-13.55M	-19.6M	-6.72M	-30.22M
Discontinued Operations	-417K	0	-7.62M	4.61M	2.89M	80K	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-7.13	-6.05	-6.64	-0.28	1.26	-2.38	-3.48	-3.93	-0.75	-3.03
EPS Growth %	-0.07%	0.15%	-0.1%	0.96%	5.5%	-2.89%	-0.46%	-0.13%	0.81%	-3.04%
EPS (Basic)	-7.13	-6.05	-6.64	-0.28	1.26	-2.38	-3.48	-3.93	-0.75	-3.03
Diluted Shares Outstanding	3.1M	3.12M	3.33M	3.87M	3.88M	3.89M	3.89M	4.99M	9.01M	9.96M
Basic Shares Outstanding	3.1M	3.12M	3.33M	3.87M	3.88M	3.89M	3.89M	4.99M	9.01M	9.96M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	50.4M	33.61M	41.52M	32.71M	35.62M	26.19M	14.95M	45.84M	49.7M	52.16M
Cash & Short-Term Investments	45.77M	30.03M	36.07M	23.63M	29.46M	21.58M	11.05M	33.9M	41.54M	43.16M
Cash Only	42.5M	28.87M	36.07M	6.72M	7.24M	17.38M	11.05M	33.9M	11.87M	9.15M
Short-Term Investments	3.27M	1.16M	0	16.92M	22.04M	4.02M	0	0	29.68M	34.01M
Accounts Receivable	2.91M	2.74M	3.44M	7.27M	4.33M	2.84M	2.27M	9.7M	4.42M	5.85M
Days Sales Outstanding	1.77K	641.68	502.46	780.01	49.77	47.63	34.82	133.56	86.32	105.63
Inventory	1.72M	844K	1.89M	1.68M	1.61M	1.38M	1.2M	1.96M	2.85M	2.69M
Days Inventory Outstanding	240.3	135.71	407.81	279.87	47.15	34.14	28.03	50.54	66	53.28
Other Current Assets	-205K	-224K	0	0	408K	257K	0	363K	167K	0
Total Non-Current Assets+	2.13M	2.15M	2.62M	2.56M	4.97M	4.88M	4.79M	4.18M	16.76M	21.33M
Property, Plant & Equipment	1.04M	1.28M	1.92M	2.02M	4.53M	4.51M	4.03M	3.58M	15.93M	20.8M
Fixed Asset Turnover	0.58x	1.22x	1.30x	1.68x	7.01x	4.82x	5.90x	7.40x	1.17x	0.97x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	896K	773K	635K	495K	429K	363K	297K	231K	165K	99K
Long-Term Investments	0	0	0	0	0	0	469K	364K	490K	439K
Other Non-Current Assets	192K	103K	56K	48K	6K	-4.88M	-4.32M	-3.81M	183K	0
Total Assets+	52.52M	35.76M	44.13M	35.28M	40.59M	31.07M	19.74M	50.02M	66.46M	73.5M
Asset Turnover	0.01x	0.04x	0.06x	0.10x	0.78x	0.70x	1.20x	0.53x	0.28x	0.28x
Asset Growth %	-0.26%	-0.32%	0.23%	-0.2%	0.15%	-0.23%	-0.36%	1.53%	0.33%	0.11%
Total Current Liabilities+	5.21M	5.38M	5.43M	4.9M	10.37M	8.27M	10.72M	12.06M	10.83M	26.54M
Accounts Payable	1.12M	1.46M	3.25M	2.71M	4.07M	2.99M	4.69M	5.66M	4.22M	4.1M
Days Payables Outstanding	157.35	234.11	702.97	452.29	118.88	74.02	109.61	145.63	97.93	81.07
Short-Term Debt	0	0	0	0	0	0	0	0	0	418K
Deferred Revenue (Current)	91K	122K	131K	198K	249K	462K	543K	63K	24K	12K
Other Current Liabilities	276K	2.24M	0	452K	3.74M	2.9M	3.85M	3.87M	1.86M	17.73M
Current Ratio	9.68x	6.25x	7.64x	6.68x	3.43x	3.17x	1.39x	3.80x	4.59x	1.97x
Quick Ratio	9.35x	6.09x	7.30x	6.34x	3.28x	3.00x	1.28x	3.64x	4.33x	1.86x
Cash Conversion Cycle	1.85K	543.27	207.3	607.59	-21.96	7.75	-46.76	38.47	54.38	77.84
Total Non-Current Liabilities+	23.85M	22.61M	29.08M	21.41M	15.05M	15.53M	13.61M	27.05M	16.74M	15.8M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	2.01M	1.74M	1.39M	846K	6.35M	6.51M
Deferred Tax Liabilities	0	0	0	0	243K	292K	288K	0	0	0
Other Non-Current Liabilities	23.85M	21.59M	28.09M	20.25M	11.91M	12.56M	12.1M	26.2M	10.39M	8.55M
Total Liabilities	29.05M	27.99M	34.52M	26.3M	25.42M	23.8M	24.33M	39.1M	34.86M	42.34M
Total Debt+	0	0	0	0	2.01M	1.74M	1.39M	846K	6.35M	6.93M
Net Debt	-42.5M	-28.87M	-36.07M	-6.72M	-5.24M	-15.63M	-9.65M	-33.05M	-5.52M	-2.22M
Debt / Equity	-	-	-	-	0.13x	0.24x	-	0.08x	0.20x	0.22x
Debt / EBITDA	-	-	-	-	0.29x	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-0.77x	-	-	-	-	-
Interest Coverage	-	-	-	-	27.37x	-44.20x	-67.19x	-47.29x	-46.27x	-34.55x
Total Equity+	23.47M	7.77M	9.62M	8.97M	15.17M	7.27M	-4.58M	10.91M	31.59M	31.15M
Equity Growth %	-0.45%	-0.67%	0.24%	-0.07%	0.69%	-0.52%	-1.63%	3.38%	1.89%	-0.01%
Book Value per Share	7.58	2.49	2.89	2.32	3.91	1.87	-1.18	2.19	3.51	3.13
Total Shareholders' Equity	23.47M	7.77M	9.62M	8.97M	15.17M	7.27M	-4.58M	10.91M	31.59M	31.15M
Common Stock	60K	60K	75K	75K	75K	75K	75K	143K	184K	215K
Retained Earnings	-88.38M	-107.26M	-129.41M	-130.72M	-125.76M	-134.96M	-148.51M	-168.11M	-174.82M	-205.05M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-16K	-9K	-38K	-25K	-17K	-40K	-19K	-5K	-18K	-11K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-19.6M	-16.45M	-16.45M	-12.15M	8.29M	-6.89M	-8.92M	-11.88M	-10.46M	-13.62M
Operating CF Margin %	-32.61%	-10.56%	-6.59%	-3.57%	0.26%	-0.32%	-0.38%	-0.45%	-0.56%	-0.67%
Operating CF Growth %	-0.19%	0.16%	-0%	0.26%	1.68%	-1.83%	-0.29%	-0.33%	0.12%	-0.3%
Net Income	-22.09M	-18.89M	-22.15M	-1.06M	4.96M	-9.2M	-13.55M	-19.6M	-6.72M	-30.22M
Depreciation & Amortization	503K	589K	567K	577K	1.15M	1.09M	1.24M	1.27M	1.3M	1.48M
Stock-Based Compensation	2.66M	3.17M	1.36M	645K	1.23M	1.32M	1.67M	1.95M	1.94M	3.14M
Deferred Taxes	90K	125K	-1.64M	201K	-1.86M	-373K	-124K	0	0	0
Other Non-Cash Items	-1.04M	-3.43M	7.85M	-11.51M	-1.69M	323K	1.69M	11.74M	-9.33M	10.71M
Working Capital Changes	275K	1.98M	-2.45M	-1.01M	4.49M	-61K	162K	-7.24M	2.34M	1.27M
Change in Receivables	-181K	-107K	28K	-211K	-3.55M	1.39M	929K	-7.58M	4.76M	-1.02M
Change in Inventory	-273K	873K	-1.04M	206K	67K	141K	257K	-721K	-906K	187K
Change in Payables	-76K	331K	-135K	-536K	1.35M	-1.1M	1.72M	414K	-594K	406K
Cash from Investing+	36.05M	1.82M	437K	-17.04M	-6.9M	17.39M	3.55M	-481K	-34.32M	-8.4M
Capital Expenditures	-406K	-701K	-1.07M	-534K	-792K	-923K	-489K	-555K	-6.46M	-6.27M
CapEx % of Revenue	0.68%	0.45%	0.43%	0.16%	0.02%	0.04%	0.02%	0.02%	0.35%	0.31%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	36.45M	2.52M	349K	-16.51M	-1.05M	274K	35K	74K	-27.86M	-2.12M
Cash from Financing+	778K	907K	23M	46K	-1.01M	-629K	-1.05M	35.76M	22.92M	19.39M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	778K	907K	337K	46K	-376K	-121K	-1.05M	-2.62M	-1.99M	-1.84M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-20.01M	-17.15M	-17.53M	-12.69M	7.5M	-7.82M	-9.4M	-12.44M	-16.93M	-19.9M
FCF Margin %	-33.29%	-11.01%	-7.02%	-3.73%	0.24%	-0.36%	-0.4%	-0.47%	-0.91%	-0.98%
FCF Growth %	-0.18%	0.14%	-0.02%	0.28%	1.59%	-2.04%	-0.2%	-0.32%	-0.36%	-0.18%
FCF per Share	-6.46	-5.49	-5.26	-3.28	1.93	-2.01	-2.42	-2.49	-1.88	-2.00
FCF Conversion (FCF/Net Income)	0.89x	0.87x	0.74x	11.50x	1.67x	0.75x	0.66x	0.61x	1.56x	0.45x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-66.59%	-120.9%	-254.73%	-11.37%	41.05%	-81.96%	-1007.51%	-619.05%	-31.6%	-96.33%
Return on Invested Capital (ROIC)	-	-	-	-	69.71%	-844.59%	-	-	-589.54%	-52.85%
Gross Margin	-333.44%	-45.7%	32.37%	35.58%	60.72%	32.21%	34.24%	46.5%	15.77%	8.81%
Net Margin	-3675.21%	-1212.13%	-887.38%	-31.08%	15.59%	-42.26%	-57.03%	-73.97%	-35.94%	-149.46%
Debt / Equity	-	-	-	-	0.13x	0.24x	-	0.08x	0.20x	0.22x
Interest Coverage	-	-	-	-	27.37x	-44.20x	-67.19x	-47.29x	-46.27x	-34.55x
FCF Conversion	0.89x	0.87x	0.74x	11.50x	1.67x	0.75x	0.66x	0.61x	1.56x	0.45x
Revenue Growth	132.05%	159.23%	60.21%	36.26%	834.7%	-31.54%	9.19%	11.5%	-29.48%	8.22%

Revenue by Geography

	2020
USA	18.03M
USA Growth	-

Frequently Asked Questions

Growth & Financials

MediWound Ltd. (MDWD) reported $20.9M in revenue for fiscal year 2024.

MediWound Ltd. (MDWD) grew revenue by 8.2% over the past year. This is steady growth.

MediWound Ltd. (MDWD) reported a net loss of $20.6M for fiscal year 2024.

Dividend & Returns

MediWound Ltd. (MDWD) has a return on equity (ROE) of -96.3%. Negative ROE indicates the company is unprofitable.

MediWound Ltd. (MDWD) had negative free cash flow of $18.0M in fiscal year 2024, likely due to heavy capital investments.